

Simulation for Decision Making: MSToolkit for Go/No Go

Chris Campbell

ccampbell@mango-solutions.com



data analysis that delivers



Agenda

- Clinical Trial Simulation
- Using MSToolkit
- Informing Decisions



Clinical Trial Simulation

Why M&S?



"I have always considered it more desirable to kill computer-generated patients than real ones while calibrating design parameters"

*Peter Thall, MD Anderson Cancer Centre,
Houston, TX*

Clinical Trial Simulation

Why M&S?



- Efficacy failures are making R&D expensive (51% Phase 2, 66% Phase 3)*
 - Differentiation against existing therapies
 - Benefit/risk & cost effectiveness
- Integrate understanding of human biology through modelling

* Current Position and Expectation for use of M&S in Drug Development and Regulatory Decision Making.
Peter A Milligan. Parallel 2c, PSI 2012

Clinical Trial Simulation

How to Approach M&S?


- MHRA support for M&S
- Regulators keen to see M&S being used
- Impact on submission based on usage



- Describe



- Justify



- Replace





Role of Modelling and Simulation in Regulatory Decision Making in Europe.
Terry Shepard. Parallel 2c, PSI 2012

Clinical Trial Simulation

How to Approach M&S?



- Low Impact: Internal decision making, verify conclusions from preclinical FTIH
- Medium Impact: Dose ranging, justify not doing a study (e.g. PBPK)
- High Impact: Extrapolating efficacy/safety in new population




Role of Modelling and Simulation in Regulatory Decision Making in Europe.
Terry Shepard. Parallel 2c, PSI 2012

Clinical Trial Simulation

How to Approach M&S?

- M&S Good Practice



Role of Modelling and Simulation in Regulatory Decision Making in Europe.
Terry Shepard. Parallel 2c, PSI 2012

M&S Good Practice Target Decision



- Know decision(s) that will be affected
- Benefits occur when decision is acted upon

Target
Decision

Seven theses about good modelling: some reflections on modelling and simulation in the pharmaceutical industry. Stig Johan Wiklund & Carl-Fredrik Burman. Poster, PSI 2012

M&S Good Practice

Apply Scientific Knowledge



- Diverse approaches may be necessary to solve problem efficiently, not statistics alone


Apply
Scientific
Knowledge

Target
Decision

Seven theses about good modelling: some reflections on modelling and simulation in the pharmaceutical industry. Stig Johan Wiklund & Carl-Fredrik Burman. Poster, PSI 2012

M&S Good Practice

Understand Question




- “All models are wrong, but some are useful”
George Box
- Incorporate information that is relevant to the decision

Seven theses about good modelling: some reflections on modelling and simulation in the pharmaceutical industry. Stig Johan Wiklund & Carl-Fredrik Burman. Poster, PSI 2012

M&S Good Practice

Keep it Simple



- “Pluralitas non est ponenda sine necessitate”
John Duns Scotus
- Do not waste effort on features that do not affect decision
- Can parts of model be replaced with analytic or numeric solutions

Seven theses about good modelling: some reflections on modelling and simulation in the pharmaceutical industry. Stig Johan Wiklund & Carl-Fredrik Burman. Poster, PSI 2012

M&S Good Practice

Diverse Information Sources



- Glean insight from where it is available



Seven theses about good modelling: some reflections on modelling and simulation in the pharmaceutical industry. Stig Johan Wiklund & Carl-Fredrik Burman. Poster, PSI 2012

M&S Good Practice Communication



- Share ideas & methods with other quantitative scientists
- Present solution, confidence intervals, assumptions, robustness checks

Seven theses about good modelling: some reflections on modelling and simulation in the pharmaceutical industry. Stig Johan Wiklund & Carl-Fredrik Burman. Poster, PSI 2012

M&S Good Practice Continuous



- Re-use, update and re-apply models in continuous integrated process

Seven theses about good modelling: some reflections on modelling and simulation in the pharmaceutical industry. Stig Johan Wiklund & Carl-Fredrik Burman. Poster, PSI 2012


Target Decision



- Is an effect present? e.g. 15 % improvement in mean over placebo
- Is an effect sufficient to justify further investment?
- Which dose should be studied next?

Enhanced Quantitative Decision Making - Reducing the Likelihood of Incorrect Decisions.
Mike K Smith, J French, MM Hutmacher, KG Kowalski, & W Ewy. PKUK 2011

What to Simulate? Target Decision



- Determine contributing factors

Using MSToolkit



- An R package to:
 - Simulate clinical trials
 - Evaluate designs
 - Analyse methodology
 - Quantify operating characteristics
 - Apply dose and study level decision criteria



Using MSToolkit Features



- Backed by Mango (validated, tests)
- Functionality:
 - Low level functions to perform basic tasks
 - High level functions to run then tweak
- Uses cluster (if available) to enhance performance
- Can use SAS (if available) for analysis

Using MSToolkit Facilitates Communication



- Developed by Mango & Pfizer in 2008, freely available
 - CRAN e.g. <http://stat.ethz.ch/CRAN/>
 - R Forge <https://r-forge.r-project.org/projects/mstoolkit/>
- Facilitate communication between M&S team
- Intuitive naming conventions facilitate communication with non-expert stakeholders

Using MSToolkit Target Decision



- Suite of low level functions - select elements needed
 - Generate possible treatments `createTreatments`
 - Allocate subjects to treatments `allocateTreatments`
 - Generate parameters `createParameters`
 - Generate covariates `createCovariates`
 - Add missingness `createMCAR`
 - Add dropout `createDropout`
 - Allocate subjects to interims `createInterims`
 - Generate responses `createResponse`

Using MSToolkit Generate Treatments



```
> seqMat                                     # dosing schedules
      [,1] [,2] [,3]
[1,]    0   15   30
[2,]   15   30    0
[3,]   30    0   15
> allTrts <- createTreatments(sequence = seqMat)
> allTrts
   TRT TIME DOSE
1   1     1    0
2   1     2   15
3   1     3   30
4   2     1   15
5   2     2   30
6   2     3    0
7   3     1   30
8   3     2    0
9   3     3   15
```

Using MSToolkit Allocate Treatments



```
> allocTrts <- allocateTreatments(trts = 3,  
+      subjects = 20, prop = c(0.2, 0.2, 0.6))  
> head(allocTrts)  
  SUBJ TRT  
1     1   3  
2     2   1  
3     3   3  
4     4   3  
5     5   3  
6     6   3  
  
> idTrts <- merge(allocTrts, allTrts)  
> head(idTrts, 3)  
  TRT SUBJ TIME DOSE  
1   1     2     2    15  
2   1     2     1     0  
3   1     2     3    30
```

Using MSToolkit

Generate Covariates



```
> idCov <- createContinuousCovariates(subjects = 20,  
+      names = c("AGE", "BMI"), mean = c(35, 24),  
+      covariance = c(30, 15), digits = c(0, 1),  
+      range = "18 <= AGE <= 55, 17 <= BMI <= 33")  
> head(idCov)                                # describe covariates  
SUBJ AGE   BMI  
1    1 31 28.0  
2    2 32 28.3  
3    3 34 26.1  
4    4 34 27.4  
5    5 31 24.0  
6    6 38 21.7  
  
> idTrts <- merge(idTrts, idCov)
```

Using MSToolkit

Creating Parameters



```
> ePars <- createNormalParameters(subjects = 20,
+      names = "E0, D50, EMAX", mean = c(100, 40, -70),
+      covariance = c(10, 12, 15), betNames = "D50, EMAX",
+      betCov = 8, errStruc = "Additive", digits = 1)
> head(ePars, 3)
  SUBJ    E0    D50   EMAX PAROMIT
1  1 97.1 40.2 -68.1        0
2  2 97.1 39.4 -64.7        0
3  3 97.1 39.3 -66.6        0

> idTrts <- merge(idTrts, ePars)
> head(idTrts)
  SUBJ TRT TIME DOSE AGE  BMI    E0    D50   EMAX PAROMIT
1    1   3     3    15   31 28.0 97.1 40.2 -68.1        0
2    1   3     1    30   31 28.0 97.1 40.2 -68.1        0
3    1   3     2     0   31 28.0 97.1 40.2 -68.1        0
4    2   1     2    15   32 28.3 97.1 39.4 -64.7        0
5    2   1     1     0   32 28.3 97.1 39.4 -64.7        0
6    2   1     3    30   32 28.3 97.1 39.4 -64.7        0
```

Using MSToolkit Response & Residual Error



```
> respData <- createResponse(data = idTrts, covariance = 35,  
+     equation = "E0 + (EMAX * DOSE) / (D50 + DOSE)",  
+     errStruc = "Additive", range = "RESP > 0")  
> allData <- cbind(idTrts, respData)  
> head(allData[-(5:6)])
```

	SUBJ	TRT	TIME	DOSE	E0	D50	EMAX	PAROMIT	RESP	RESPOMIT	
1	1	3	3	15	97.1	40.2	-68.1		0	79.751	0
2	1	3	1	30	97.1	40.2	-68.1		0	72.709	0
3	1	3	2	0	97.1	40.2	-68.1		0	95.252	0
4	2	1	2	15	97.1	39.4	-64.7		0	70.173	0
5	2	1	1	0	97.1	39.4	-64.7		0	89.553	0
6	2	1	3	30	97.1	39.4	-64.7		0	69.205	0

Using MSToolkit Create a Single Trial



singleTrial.csv - Microsoft Excel

The screenshot shows a Microsoft Excel window with the title bar "singleTrial.csv - Microsoft Excel". The ribbon menu is visible with tabs like File, Home, Insert, etc. The main area displays a data table with 7 rows and 12 columns. The columns are labeled A through L, and the first row contains the header "SUBJ". The data includes various numerical values such as 1, 3, 15, 31, 28, 97.1, 40.2, -68.1, 0, 79.751, 0, 1, 3, 1, 30, 31, 28, 97.1, 40.2, -68.1, 0, 72.709, 0, 1, 3, 2, 0, 31, 28, 97.1, 40.2, -68.1, 0, 95.252, 0, 2, 1, 2, 15, 32, 28.3, 97.1, 39.4, -64.7, 0, 70.173, 0, 2, 1, 1, 0, 32, 28.3, 97.1, 39.4, -64.7, 0, 89.553, 0, and 2, 1, 3, 30, 32, 28.3, 97.1, 39.4, -64.7, 0, 69.205, 0.

A	B	C	D	E	F	G	H	I	J	K	L
1	SUBJ	TRT	TIME	DOSE	AGE	BMI	E0	D50	EMAX	PAROMIT	RESP
2	1	3	3	15	31	28	97.1	40.2	-68.1	0	79.751
3	1	3	1	30	31	28	97.1	40.2	-68.1	0	72.709
4	1	3	2	0	31	28	97.1	40.2	-68.1	0	95.252
5	2	1	2	15	32	28.3	97.1	39.4	-64.7	0	70.173
6	2	1	1	0	32	28.3	97.1	39.4	-64.7	0	89.553
7	2	1	3	30	32	28.3	97.1	39.4	-64.7	0	69.205

Using MSToolkit Or use High Level Function



```
> generateData(replicateN = 100, subjects = 20,  
+   workingPath = "C:/Temp/New Simulation",  
+   treatDoses = c(0, 5, 25, 50, 100),  
+   conCovNames = c("WGT", "AGE"), conCovMean = c(83, 55),  
+   conCovVCov = c(13, 9)^2, conCovDigits = 1,  
+   conCovCrit = "18 <= AGE <= 65",  
+   genParNames = "E0, D50, EMAX", genParMean = c(2, 50, 10),  
+   genParVCov = diag(c(0.5, 30, 10)),  
+   genParBtwNames = "E0, D50, EMAX", genParBtwMean = c(0, 0, 0),  
+   genParBtwVCov = diag(c(0.4, 5, 2)),  
+   respEqn = "E0 + (DOSE * EMAX) / (DOSE + D50)",  
+   respVCov = 5,  
+   interimSubj = "0.3, 0.7")
```

Using MSToolkit To Generate Replicates



The screenshot shows the MSToolkit interface. The file browser window displays a folder structure: Computer > OS (C) > Temp > New Simulation > ReplicateData. Inside this folder are seven CSV files named replicate0001.csv through replicate0007.csv. The file replicate0001.csv is currently open in Microsoft Excel, showing the following data:

	A	B	C	D	E	F	G	H	I	J	K	L
1	SUBJ	TRT	DOSE	WGT	AGE	E0	D50	EMAX	E0.Between	D50.Between	EMAX.Bet	PARC
2	1	5	100	69.4	48.5	2.258	53.711	12.765	0.057	-0.66	-1.728	
3	2	1	0	113.7	50.7	2.258	53.711	12.765	-0.214	-1.219	1.869	
4	3	3	25	95	58	2.258	53.711	12.765	1.097	-3.672	-0.537	
5	4	1	0	88.4	45.9	2.258	53.711	12.765	1.574	-2.434	1.059	
6	5	4	50	71.6	63.1	2.258	53.711	12.765	-0.779	-2.667	-1.166	
7	6	3	25	85.6	50.5	2.258	53.711	12.765	-0.633	1.722	-0.028	
8	7	5	100	74.6	53.4	2.258	53.711	12.765	-0.543	-1.26	-1.375	
9	8	4	50	102.8	45.9	2.258	53.711	12.765	-0.143	-2.5	-0.29	
10	9	4	50	76.3	63.6	2.258	53.711	12.765	-0.626	-3.531	-0.283	

At the bottom left of the MSToolkit interface, the website address www.mango-solutions.com is visible.

Using MSToolkit Data Output




```
> getEctdDataMethod( )  
[1] "Internal"  
  
> setEctdDataMethod( "CSV" )
```

- Text files (csv)
- Data files (RData)
- Retained internally in memory for increased speed

Using MSToolkit Analyze Data



```
> meanFun <- function(data) { as.data.frame(t(data$MEAN)) }  
  
> analyzeData(analysisCode = parallel,  
+               macroCode = meanFun,  
+               grid = FALSE)
```



Apply Scientific Knowledge



- Preclinical information about this drug
- Incorporate description of disease
- Competitor or literature information about other drugs in class

Target Decision

Quantitative Go/No Go



```
> macrocode <- function(data, Threshold = -3.2) {  
+   out <- data$LOWER > Threshold  
+   out <- as.data.frame(t(out))  
+   names(out) <- paste("GO", data$DOSE, sep = "")  
+   return(out)  
+ }
```

- Go if lower confidence interval of response is greater than threshold response -3.2

PSI M&S SIG Software Hands on Session

Mike K Smith. 17th November 2010


www.mango-solutions.com

Informing Decisions Prior Information



```
> group <- rep(c(0, log(750)), each = 10)
> placebo <- c(-1.6, 1.3, 5.7, -0.1, -3.3, -1, 5.6, 2, -0.4, -3.2)
> active <- c(-7.1, -8.7, -6.8, 1.3, -0.6, 3, -3.9, -6.2, -4, -0.2)
> response <- c(placebo, active)

> xyplot(response ~ group,
+         panel = customPanel,
+         axis = axis.smart,
+         xlab = "log(dose)",
+         xlim = c(-0.5, 7))
```




PSI M&S SIG Software Hands on Session

Mike K Smith. 17th November 2010

Informing Decisions Estimate Parameters

```
> mod <- lm(response ~ group)
> sumMod <- summary(mod)
> coefMod <- coef(mod)
> varMod <- sumMod$sigma^2
> vcov <- varMod * sumMod$cov # scaled varcov matrix

> xyplot(response ~ group,
+         panel = lmCustomPanel,
+         coef = coefMod,
+         axis = axis.smart,
+         xlab = "log(dose)" ,
+         xlim = c(-0.5, 7))
```



PSI M&S SIG Software Hands on Session

Mike K Smith. 17th November 2010

Informing Decisions

Define Analysis



```
> parallel <- function(data) {  
+   analys <- lm(RESP ~ log(DOSE), data = data)  
+   sumAnalys <- summary(analys)  
+   doses <- sort(unique(data$DOSE))  
+   fitted <- predict.lm(analys, newdata = list(DOSE = doses),  
+     se.fit = TRUE, interval = "confidence", level = 0.95)  
+  
+   mn <- fitted$fit[, 1]  
+   n <- tapply(data$RESP, list(data$DOSE), length)  
+   INTER <- unique(data$INTER)  
+   SLOPE <- unique(data$SLOPE)  
+   TRUTH <- INTER + SLOPE * log(doses)  
+  
+   outDf <- data.frame(  
+     DOSE = doses, MEAN = mn, SE = fitted$se.fit,  
+     LOWER = fitted$fit[, 2], UPPER = fitted$fit[, 3],  
+     N = n, TRUTH = TRUTH, INTER = INTER, SLOPE = SLOPE)  
+   return(outDf)  
+ }
```

Informing Decisions Simulate Data




```
> getEctdDataMethod()
[1] "Internal"

> generateData(replicateN = 500,
+                 subjects = 60, treatSubj = rep(10, 6),
+                 treatDoses = c(0.1, 5, 20, 75, 250, 750),
+                 genParNames = "INTER, SLOPE",
+                 genParMean = as.vector(coefMod),
+                 genParVCov = vcov,
+                 respEqn = "INTER + SLOPE * log(DOSE)",
+                 respVCov = varMod,
+                 seed = 344860)
```

Informing Decisions Visualise Data

```
> analyzeData(analysisCode = parallel,  
+               macroCode = function(data) { as.data.frame(t(data$MEAN)) } ,  
+               grid = FALSE)  
  
> dataSum <- read.csv("macroSummary.csv")  
> doses <- sort(unique(.ecltEnv$DataStore[[1]]$DOSE))  
> dataStack <- stack(dataSum,  
+                     select = -Replicate)  
> dataStack$ind <- log(doses)[dataStack$ind]  
  
> xyplot(values ~ ind, dataStack,  
+         panel = customPanel,  
+         axis = axis.smart,  
+         xlab = "log(dose)" ,  
+         xlim = c(-0.5, 7))
```



Informing Decisions

Analyze Data



```
> analyzeData(analysisCode = parallel,  
+               macroCode = macrocode, grid = FALSE)  
  
> datasum <- read.csv("macroSummary.csv")  
  
> apply(datasum[-1], 2, mean)  
GO0.1   GO5   GO20   GO75  GO250 GO750  
0.966  0.954  0.844  0.562  0.278  0.114
```

Informing Decisions



- Design a trial and simulate data
- Compare performance metrics with deterministic outcome
- Characterise probability of making correct/incorrect decision using:
 - statistical significance & Type I/Type II errors or
 - reference to clinical decision efficacy or tolerability

Communication Demonstrate Alternatives



- What if data generating process is nonlinear but the data are analysed using a linear model?
- Examine robustness when assumptions change compared to initial assumptions

Conclusion



- Good Practice during M&S will make it easier to support submission
- MSToolkit provides:
 - quick to learn & easily shared data generation tools
 - a reusable but flexible framework for analysing systems to inform go/no go decisions

Acknowledgements



- Rich Pugh (Mango Solutions)
- Mike Smith (Pfizer)
- Stig Johan Wiklund (Astrazeneca)
- Carl-Fredrik Burman (Astrazeneca)

References



Current Position and Expectation for use of M&S in Drug Development and Regulatory Decision Making. Peter A Milligan. Parallel 2c, PSI 2012

Role of Modelling and Simulation in Regulatory Decision Making in Europe. Terry Shepard. Parallel 2c, PSI 2012

Seven theses about good modelling: some reflections on modelling and simulation in the pharmaceutical industry. Stig Johan Wiklund & Carl-Fredrik Burman. Poster, PSI 2012

Enhanced Quantitative Decision Making - Reducing the Likelihood of Incorrect Decisions. Mike K Smith, J French, MM Hutmacher, KG Kowalski, & W Ewy. PKUK 2011

PSI M&S SIG Software Hands on Session. Mike K Smith. 17th November 2010

Basel R

<http://www.baselr.org/>



- Date: Thursday 13th September
- Time: 6.30 pm (presentations begin at 7 pm)
- Venue: transBarent, Viaduktstrasse 3, Basel 4051
- Presentations:
 - Calling R from .NET: a case-study using Rapid NCA, the non-compartmental analysis workflow tool
 - Chris Campbell
 - R as the weapon of choice for a simulation case study of a step-wedge design
 - MariaBeth Silkey



Questions

Chris Campbell

ccampbell@mango-solutions.com

